U.S. markets closed

Humanigen, Inc. (HGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2600+0.0200 (+0.89%)
At close: 04:00PM EDT
2.4400 +0.18 (+7.96%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2400
Bid2.3600 x 3200
Ask2.2500 x 1800
Day's Range2.0850 - 2.3300
52 Week Range1.6700 - 23.5300
Avg. Volume1,574,561
Market Cap144.229M
Beta (5Y Monthly)-1.47
PE Ratio (TTM)N/A
EPS (TTM)-4.2280
Earnings DateMar 08, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.75
  • TipRanks

    Humanigen: A ‘Transformative Year’ Awaits, Says Analyst

    Accounting for many stocks losing a huge chunk of their valuations in 2022’s inhospitable stock market, analysts have been busy slashing estimates and price targets this year. However, for H.C. Wainwright analyst Joseph Pantginis, there has been no such change of heart when considering the prospects of biotech company Humanigen (HGEN). Even in the face of FDA rejection and a stock which is down 89% over the past year, Pantginis remains undeterred. The analyst reiterated a Buy rating for HGEN sto

  • Simply Wall St.

    Investors in Humanigen (NASDAQ:HGEN) from a year ago are still down 89%, even after 14% gain this past week

    It's nice to see the Humanigen, Inc. ( NASDAQ:HGEN ) share price up 14% in a week. But that doesn't change the fact...

  • Business Wire

    Humanigen Reports First Quarter 2022 Financial Results

    SHORT HILLS, N.J., May 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.